A randomized, double-blind, placebo controlled, period III medical trial evaluated the efficacy and protection profile of adalimumab for a monotherapy in people with RA who had failed to answer csDMARDs [191]. The final results confirmed the two statistically major advancement during the disease exercise and a fantastic basic safety profile. https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/